{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:12:08Z","timestamp":1776719528765,"version":"3.51.2"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,27]]},"DOI":"10.7759\/cureus.51183","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T20:24:58Z","timestamp":1703708698000},"source":"Crossref","is-referenced-by-count":6,"title":["A Narrative Review of Osteonecrosis of the Jaw: What a Clinician Should Know"],"prefix":"10.7759","author":[{"given":"Swati","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Sarat","family":"Ravi Kiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Breh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shitun","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amitabh","family":"Kumar Upadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/njms.NJMS_236_20","article-title":"Medication-related osteonecrosis of the jaw: an update","volume":"13","author":"Bansal H","year":"2022","unstructured":"Bansal H. Medication-related osteonecrosis of the jaw: an update. Natl J Maxillofac Surg. 2022, 13:5-10. 10.4103\/njms.NJMS_236_20","journal-title":"Natl J Maxillofac Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204762","article-title":"Cancer patients at risk for medication-related osteonecrosis of the jaw. A case and control study analyzing predictors of MRONJ onset","volume":"10","author":"Marcian\u00f2 A","year":"2021","unstructured":"Marcian\u00f2 A, Ingrasciotta Y, Isgr\u00f2 V, et al.. Cancer patients at risk for medication-related osteonecrosis of the jaw. A case and control study analyzing predictors of MRONJ onset. J Clin Med. 2021, 10:10.3390\/jcm10204762","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115901","article-title":"Adverse events associated with bone-directed therapies in patients with cancer","volume":"158","author":"Jara MA","year":"2022","unstructured":"Jara MA, Varghese J, Hu MI. Adverse events associated with bone-directed therapies in patients with cancer. Bone. 2022, 158:115901. 10.1016\/j.bone.2021.115901","journal-title":"Bone"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/app11177781","article-title":"Medication-related osteonecrosis of the jaw\u2014a continuing issue","volume":"11","author":"Wr\u00f3bel K","year":"2021","unstructured":"Wr\u00f3bel K, Sikora M, Ch\u0119ci\u0144ski M, Jas M, Chlubek D. Medication-related osteonecrosis of the jaw\u2014a continuing issue. Appl Sci. 2021, 11:7781. 10.3390\/app11177781","journal-title":"Appl Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1558452","article-title":"\u201cPhossy jaw\u201d and \u201cbis-phossy jaw\u201d of the 19th and the 21st centuries: the diuturnity of John Walker and the friction match","volume":"8","author":"Pollock RA","year":"2015","unstructured":"Pollock RA, Brown TW Jr, Rubin DM. \u201cPhossy jaw\u201d and \u201cbis-phossy jaw\u201d of the 19th and the 21st centuries: the diuturnity of John Walker and the friction match. Craniomaxillofac Trauma Reconstr. 2015, 8:262-70. 10.1055\/s-0035-1558452","journal-title":"Craniomaxillofac Trauma Reconstr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom N","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, et al.. Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol. 2019, 37:2270-90. 10.1200\/JCO.19.01186","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo JC","year":"2010","unstructured":"Lo JC, O'Ryan FS, Gordon NP, et al.. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010, 68:243-53. 10.1016\/j.joms.2009.03.050","journal-title":"J Oral Maxillofac Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2010.0082","article-title":"The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program","volume":"141","author":"Grbic JT","year":"2010","unstructured":"Grbic JT, Black DM, Lyles KW, et al.. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010, 141:1365-70. 10.14219\/jada.archive.2010.0082","journal-title":"J Am Dent Assoc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos S","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, et al.. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012, 27:694-701. 10.1002\/jbmr.1479","journal-title":"J Bone Miner Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti GV","year":"2012","unstructured":"Scagliotti GV, Hirsh V, Siena S, et al.. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012, 7:1823-9. 10.1097\/JTO.0b013e31826aec2b","journal-title":"J Thorac Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos K","year":"2009","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E, et al.. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009, 27:5356-62. 10.1200\/JCO.2009.21.9584","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi WX","year":"2014","unstructured":"Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014, 19:403-10. 10.1007\/s10147-013-0561-6","journal-title":"Int J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1429-y","article-title":"Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II\/III breast cancer","volume":"127","author":"Coleman R","year":"2011","unstructured":"Coleman R, Woodward E, Brown J, et al.. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II\/III breast cancer. Breast Cancer Res Treat. 2011, 127:429-38. 10.1007\/s10549-011-1429-y","journal-title":"Breast Cancer Res Treat"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0432-z","article-title":"Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis","volume":"116","author":"Mauri D","year":"2009","unstructured":"Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat. 2009, 116:433-9. 10.1007\/s10549-009-0432-z","journal-title":"Breast Cancer Res Treat"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri V","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, et al.. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010, 122:181-8. 10.1007\/s10549-010-0866-3","journal-title":"Breast Cancer Res Treat"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0022034514560768","article-title":"Diabetes as a risk factor for medication-related osteonecrosis of the jaw","volume":"94","author":"Peer A","year":"2015","unstructured":"Peer A, Khamaisi M. Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res. 2015, 94:252-60. 10.1177\/0022034514560768","journal-title":"J Dent Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/725249","article-title":"Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication","volume":"2012","author":"Caramaschi P","year":"2012","unstructured":"Caramaschi P, Biasi D, Dal Forno I, Adami S. Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication. Autoimmune Dis. 2012, 2012:725249. 10.1155\/2012\/725249","journal-title":"Autoimmune Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1086\/656412","article-title":"Bone disease in HIV infection: a practical review and recommendations for HIV care providers","volume":"51","author":"McComsey GA","year":"2010","unstructured":"McComsey GA, Tebas P, Shane E, et al.. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010, 51:937-46. 10.1086\/656412","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.01.025","article-title":"Pathophysiology and natural history of avascular necrosis of bone","volume":"73","author":"Lafforgue P","year":"2006","unstructured":"Lafforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine. 2006, 73:500-7. 10.1016\/j.jbspin.2006.01.025","journal-title":"Joint Bone Spine"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:25:1:13","article-title":"Osteonecrosis in patients with SLE","volume":"25","author":"Abu-Shakra M","year":"2003","unstructured":"Abu-Shakra M, Buskila D, Shoenfeld Y. Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol. 2003, 25:13-24. 10.1385\/CRIAI:25:1:13","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref21","article-title":"Bisphosphonate Related Jaw Osteonecrosis","author":"Gupta M","year":"2023","unstructured":"Gupta M, Gupta N. Bisphosphonate Related Jaw Osteonecrosis. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2017.12.016","article-title":"Osteonecrosis of the jaw unrelated to medication or radiotherapy","volume":"125","author":"Gadiwalla Y","year":"2018","unstructured":"Gadiwalla Y, Patel V. Osteonecrosis of the jaw unrelated to medication or radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018, 125:446-53. 10.1016\/j.oooo.2017.12.016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.12968\/denu.2016.43.6.563","article-title":"Spontaneous osteonecrosis of the maxilla","volume":"43","author":"Henien M","year":"2016","unstructured":"Henien M, Patel V, Sproat C, McGurk N. Spontaneous osteonecrosis of the maxilla. Dent Update. 2016, 43:563-4, 566. 10.12968\/denu.2016.43.6.563","journal-title":"Dent Update"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/dj11010023","article-title":"Osteonecrosis of the jaw","volume":"11","author":"Lon\u010dar Brzak B","year":"2023","unstructured":"Lon\u010dar Brzak B, Horvat Aleksijevi\u0107 L, Vindi\u0161 E, Kordi\u0107 I, Grani\u0107 M, Vidovi\u0107 Juras D, Andabak Rogulj A. Osteonecrosis of the jaw. Dent J (Basel). 2023, 11:23. 10.3390\/dj11010023","journal-title":"Dent J (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldaa005","article-title":"The epidemiology of osteoporosis","volume":"133","author":"Clynes MA","year":"2020","unstructured":"Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. Br Med Bull. 2020, 133:105-17. 10.1093\/bmb\/ldaa005","journal-title":"Br Med Bull"},{"key":"ref26","article-title":"Osteoporosis: a review of treatment options","volume":"43","author":"Tu KN","year":"2018","unstructured":"Tu KN, Lie JD, Wan CK, et al.. Osteoporosis: a review of treatment options. P T. 2018, 43:92-104.","journal-title":"P T"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3657","article-title":"Diagnosis and management of Paget\u2019s disease of bone in adults: a clinical guideline","volume":"34","author":"Ralston SH","year":"2019","unstructured":"Ralston SH, Corral-Gudino L, Cooper C, et al.. Diagnosis and management of Paget\u2019s disease of bone in adults: a clinical guideline. J Bone Miner Res. 2019, 34:579-604. 10.1002\/jbmr.3657","journal-title":"J Bone Miner Res"},{"key":"ref28","article-title":"Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases","volume":"3","author":"Polascik TJ","year":"2009","unstructured":"Polascik TJ. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther. 2009, 3:27-40.","journal-title":"Drug Des Devel Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman R","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, et al.. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020, 31:1650-63. 10.1016\/j.annonc.2020.07.019","journal-title":"Ann Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06672-3","article-title":"Management of bone loss due to endocrine therapy during cancer treatment","volume":"34","author":"Khan MI","year":"2023","unstructured":"Khan MI. Management of bone loss due to endocrine therapy during cancer treatment. Osteoporos Int. 2023, 34:671-80. 10.1007\/s00198-023-06672-3","journal-title":"Osteoporos Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100355","article-title":"Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer","volume":"28","author":"Waqas K","year":"2021","unstructured":"Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol. 2021, 28:100355. 10.1016\/j.jbo.2021.100355","journal-title":"J Bone Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S83681","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","author":"Sternlicht H","year":"2015","unstructured":"Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag. 2015, 11:1779-88. 10.2147\/TCRM.S83681","journal-title":"Ther Clin Risk Manag"},{"key":"ref33","article-title":"Giant cell tumor of bone - an overview","volume":"4","author":"Sobti A","year":"2016","unstructured":"Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant cell tumor of bone - an overview. Arch Bone Jt Surg. 2016, 4:2-9.","journal-title":"Arch Bone Jt Surg"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.coms.2015.06.001","article-title":"Pathophysiology of osteonecrosis of the jaws","volume":"27","author":"Aghaloo T","year":"2015","unstructured":"Aghaloo T, Hazboun R, Tetradis S. Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am. 2015, 27:489-96. 10.1016\/j.coms.2015.06.001","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2016.11.011","article-title":"Bacterial diversity in medication-related osteonecrosis of the jaw","volume":"123","author":"Hallmer F","year":"2017","unstructured":"Hallmer F, Bj\u00f8rnland T, Andersson G, Becktor JP, Kristoffersen AK, Enersen M. Bacterial diversity in medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017, 123:436-44. 10.1016\/j.oooo.2016.11.011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.04.015","article-title":"Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity","volume":"117","author":"Lugassy G","year":"2004","unstructured":"Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med. 2004, 117:440-1. 10.1016\/j.amjmed.2004.04.015","journal-title":"Am J Med"},{"key":"ref37","article-title":"Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy","volume":"71","author":"Melo MD","year":"2005","unstructured":"Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005, 71:111-3.","journal-title":"J Can Dent Assoc"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-007-0516-2","article-title":"Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis","volume":"451","author":"Hansen T","year":"2007","unstructured":"Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ. Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch. 2007, 451:1009-17. 10.1007\/s00428-007-0516-2","journal-title":"Virchows Arch"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad F","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, et al.. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012, 23:1341-7. 10.1093\/annonc\/mdr435","journal-title":"Ann Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/idj.12318","article-title":"Osteoradionecrosis of the jaws: definition, epidemiology, staging and clinical and radiological findings. A concise review","volume":"68","author":"Chronopoulos A","year":"2018","unstructured":"Chronopoulos A, Zarra T, Ehrenfeld M, Otto S. Osteoradionecrosis of the jaws: definition, epidemiology, staging and clinical and radiological findings. A concise review. Int Dent J. 2018, 68:22-30. 10.1111\/idj.12318","journal-title":"Int Dent J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdsr.2018.11.001","article-title":"Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws\/medication-related osteonecrosis of the jaw (secondary publication)","volume":"55","author":"Baba A","year":"2019","unstructured":"Baba A, Ojiri H, Goto TK, Ikeda K, Yamauchi H, Ogino N, Mogami T. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws\/medication-related osteonecrosis of the jaw (secondary publication). Jpn Dent Sci Rev. 2019, 55:58-64. 10.1016\/j.jdsr.2018.11.001","journal-title":"Jpn Dent Sci Rev"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2147\/CCIDE.S288603","article-title":"Osteonecrosis of the jaw beyond bisphosphonates: are there any unknown local risk factors?","volume":"13","author":"Lechner J","year":"2021","unstructured":"Lechner J, von Baehr V, Zimmermann B. Osteonecrosis of the jaw beyond bisphosphonates: are there any unknown local risk factors?. Clin Cosmet Investig Dent. 2021, 13:21-37. 10.2147\/CCIDE.S288603","journal-title":"Clin Cosmet Investig Dent"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-020-0088-1","article-title":"Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors","volume":"8","author":"Wan JT","year":"2020","unstructured":"Wan JT, Sheeley DM, Somerman MJ, Lee JS. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone Res. 2020, 8:14. 10.1038\/s41413-020-0088-1","journal-title":"Bone Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.adaj.2019.03.006","article-title":"Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: systematic review and meta-analysis","volume":"150","author":"Awad ME","year":"2019","unstructured":"Awad ME, Sun C, Jernigan J, Elsalanty M. Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: systematic review and meta-analysis. J Am Dent Assoc. 2019, 150:664-675.e8. 10.1016\/j.adaj.2019.03.006","journal-title":"J Am Dent Assoc"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10020195","article-title":"Conservative management of medication-related osteonecrosis of the jaws (MRONJ): a retrospective cohort study","volume":"10","author":"Varoni EM","year":"2021","unstructured":"Varoni EM, Lombardi N, Villa G, Pispero A, Sardella A, Lodi G. Conservative management of medication-related osteonecrosis of the jaws (MRONJ): a retrospective cohort study. Antibiotics (Basel). 2021, 10:195. 10.3390\/antibiotics10020195","journal-title":"Antibiotics (Basel)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim IW","year":"2020","unstructured":"Sim IW, Borromeo GL, Tsao C, et al.. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol. 2020, 38:2971-80. 10.1200\/JCO.19.02192","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/odi.12489","article-title":"Hyperbaric oxygen therapy and osteonecrosis","volume":"23","author":"Ceponis P","year":"2017","unstructured":"Ceponis P, Keilman C, Guerry C, Freiberger JJ. Hyperbaric oxygen therapy and osteonecrosis. Oral Dis. 2017, 23:141-51. 10.1111\/odi.12489","journal-title":"Oral Dis"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17238801","article-title":"Surgical treatment of medication-related osteonecrosis of the jaw: a retrospective study","volume":"17","author":"Choi NR","year":"2020","unstructured":"Choi NR, Lee JH, Park JY, Hwang DS. Surgical treatment of medication-related osteonecrosis of the jaw: a retrospective study. Int J Environ Res Public Health. 2020, 17:8801. 10.3390\/ijerph17238801","journal-title":"Int J Environ Res Public Health"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2019.12.018","article-title":"Surgical treatment of osteonecrosis of the jaw: an emerging problem in the era of bisphosphonates","volume":"78","author":"Hung KS","year":"2020","unstructured":"Hung KS, Sheckter CC, Gaudilliere D, Suarez P, Curtin C. Surgical treatment of osteonecrosis of the jaw: an emerging problem in the era of bisphosphonates. J Oral Maxillofac Surg. 2020, 78:682-3. 10.1016\/j.joms.2019.12.018","journal-title":"J Oral Maxillofac Surg"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjorl.2021.04.004","article-title":"Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients","volume":"88","author":"\u015eahin O","year":"2022","unstructured":"\u015eahin O, Akan E, Tatar B, Ekmekcio\u011flu C, \u00dcnal N, Odaba\u015f\u0131 O. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Braz J Otorhinolaryngol. 2022, 88:613-20. 10.1016\/j.bjorl.2021.04.004","journal-title":"Braz J Otorhinolaryngol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41368-020-00093-2","article-title":"Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw","volume":"12","author":"He L","year":"2020","unstructured":"He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci. 2020, 12:30. 10.1038\/s41368-020-00093-2","journal-title":"Int J Oral Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/214691-a-narrative-review-of-osteonecrosis-of-the-jaw-what-a-clinician-should-know","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:47Z","timestamp":1707509507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/214691-a-narrative-review-of-osteonecrosis-of-the-jaw-what-a-clinician-should-know"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.51183","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}